The estimated Net Worth of David A Green is at least $1.36 Million dollars as of 21 December 2018. Mr. Green owns over 3,330 units of Aytu BioPharma Inc stock worth over $668,288 and over the last 16 years he sold AYTU stock worth over $2,697. In addition, he makes $685,988 as Chief Financial Officer, Treasurer, and Secretary at Aytu BioPharma Inc.
Sign up
Mr. Green AYTU stock SEC Form 4 insiders trading
David has made over 2 trades of the Aytu BioPharma Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 3,330 units of AYTU stock worth $2,697 on 21 December 2018.
The largest trade he's ever made was buying 66,600 units of Aytu BioPharma Inc stock on 6 March 2018 worth over $29,970. On average, David trades about 6,357 units every 26 days since 2008. As of 21 December 2018 he still owns at least 266,250 units of Aytu BioPharma Inc stock.
You can see the complete history of Mr. Green stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
David Green biography
David A. Green CPA is Chief Financial Officer, Treasurer, Secretary of the Company. Mr. Green has served as our Chief Financial Officer, Secretary and Treasurer since December 18, 2017. Prior to joining the Company, Mr. Green served as Chief Accounting Officer from May 2016 until February 2017 at Intarcia Therapeutics, Inc., a biopharmaceutical company currently engaged in late stage clinical development. Mr. Green was a Consultant at DAG Advisors, a position he held since October 2014. From February 2012 until October 2014, he was Chief Financial Officer of Catheter Connections, a commercial-stage medical device company that was acquired by Merit Medical. Preceding Catheter Connections, Mr. Green was CFO at Specialized Health Products International, a publicly traded medical device company that was acquired by C.R. Bard. Prior to his time serving in senior financial leadership roles at commercial-stage specialty life sciences companies, Mr. Green was a Managing Director at Duff & Phelps, a global investment banking and corporate finance advisory firm for nearly a decade. Mr. Green was also a founding member of Ernst & Young's Palo Alto Center for Strategic Transactions, where he advised the firm's clients on using strategic transactions to accelerate growth. Mr. Green earned a Bachelor of Science from the State University of New York, a Master of Business Administration from the University of Rochester, and is a Certified Public Accountant.
What is the salary of David Green?
As the Chief Financial Officer, Treasurer, and Secretary of Aytu BioPharma Inc, the total compensation of David Green at Aytu BioPharma Inc is $685,988. There are 3 executives at Aytu BioPharma Inc getting paid more, with Joshua Disbrow having the highest compensation of $1,043,700.
How old is David Green?
David Green is 57, he's been the Chief Financial Officer, Treasurer, and Secretary of Aytu BioPharma Inc since 2017. There are 3 older and 7 younger executives at Aytu BioPharma Inc. The oldest executive at Aytu BioPharma Inc is Michael Macaluso, 67, who is the Independent Director.
What's David Green's mailing address?
David's mailing address filed with the SEC is C/O AYTU BIOSCIENCE, INC., 373 INVERNESS PARKWAY, SUITE 206, ENGLEWOOD, CO, 80112.
Insiders trading at Aytu BioPharma Inc
Over the last 9 years, insiders at Aytu BioPharma Inc have traded over $40,722,795 worth of Aytu BioPharma Inc stock and bought 8,465,326 units worth $11,497,374 . The most active insiders traders include Capital, Llc Armistice Capi..., Carl Dockery, and Joshua R. Disbrow. On average, Aytu BioPharma Inc executives and independent directors trade stock every 91 days with the average trade being worth of $2,701,531. The most recent stock trade was executed by Greg Pyszczymuka on 30 June 2024, trading 208 units of AYTU stock currently worth $522.
What does Aytu BioPharma Inc do?
aytu bioscience is a specialty healthcare company focused on developing and commercializing novel products in the field of urology. aytu is initially concentrating on prostate cancer, male premature ejaculation and male infertility and plans to expand into other urological indications for which there are significant medical needs. the company currently markets prostascint®, an fda-approved radioimaging agent indicated to detect prostate specific membrane antigen (psma) in the assessment and staging of prostate cancer. the company’s most advanced therapeutic is zertane™, an oral therapeutic entering phase 3 clinical studies in the united states as an as needed treatment for premature ejaculation (pe). aytu is also conducting clinical trials with the company’s mioxsys™ system as a novel, point-of-care diagnostic system with the potential to become a standard of care in the diagnosis and management of male infertility.
What does Aytu BioPharma Inc's logo look like?
Complete history of Mr. Green stock trades at SJW and Aytu BioPharma Inc
Aytu BioPharma Inc executives and stock owners
Aytu BioPharma Inc executives and other stock owners filed with the SEC include:
-
Joshua Disbrow,
Chairman of the Board, Chief Executive Officer -
Joshua R. Disbrow,
Chairman & CEO -
Jarrett Disbrow,
Chief Operating Officer -
David Green,
Chief Financial Officer, Treasurer, Secretary -
Michael Macaluso,
Independent Director -
John Donofrio,
Independent Director -
Carl Dockery,
Independent Director -
Gary Cantrell,
Independent Director -
Ketan Mehta,
Director -
James Carbonara,
IR Contact Officer -
Steven Boyd,
Director -
Matthew Phillips,
Executive Vice President - Commercial Operations -
Russ McMahen,
Sr. VP of R&D -
Topher Brooke,
Exec. VP of Rare Disease Devel. -
Nate Massari,
Exec. VP of Rare Disease Operations -
Greg Pyszczymuka,
Chief Commercial Officer -
Jarrett T. Disbrow Ph.D.,
Exec. VP of Corp. Operations -
Beth Hecht,
Director -
Gerald W. Mc Laughlin,
Director -
Inc. Cerecor,
10% owner -
Capital Management, Llc Har...,
-
Gregory A Gould,
Chief Financial Officer -
Jonathan H Mc Grael,
Vice President of Sales -
Pharmaceuticals, Inc. Ampio,
10% owner -
Mark K Oki,
Chief Financial Officer -
Greg Pyszczymuka,
Chief Commercial Officer -
Christopher Brooke,
Chief Operating Officer -
Abhinav Jain,
-
Vivian H Liu,
-
Richard I Eisenstadt,
Chief Financial Officer